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Abstract
Background: Marginal zone (MZ) B cells play important roles in the early phases of humoral
immune responses. In addition to possessing an inherent capacity to rapidly differentiate into
antibody secreting cells, MZ B cells also help to regulate the fate of both T-independent and T-
dependent blood-borne antigens in the spleen. For T-dependent antigens, MZ B cells bind IgM-
antigen complexes in a complement-dependent manner. Once MZ B cells bind IgM-containing
immune complexes (IgM-IC), they transport them into B cell follicles for deposition onto follicular
dendritic cells (FDCs), an important component of secreted IgM's ability to enhance adaptive
immune responses. To further define the requirement for MZ B cells in IgM-IC deposition, mice
deficient in the NF-κB protein p50, which have been reported to lack MZ B cells, were analyzed
for their ability to trap IgM-IC onto FDCs.
Results: Mice (2 months of age) deficient in p50 (p50-/-) had small numbers of MZ B cells, as
determined by cell surface phenotype and localization in the splenic MZ. These cells bound high
levels of IgM-IC both in vivo and in vitro. Subsequent to the binding of IgM-IC by the MZ B cells in
p50-/- mice, small amounts of IgM-IC were found localized on FDCs, suggesting that the MZ B cells
retained their ability to transport these complexes into splenic follicles. Strikingly, MZ B cells
accumulated with age in p50-/- mice. By 6 months of age, p50-/- mice contained normal numbers of
these cells as defined by CD21/CD23 profile and high level expression of CD1d, CD9, and IgM, and
by their positioning around the marginal sinus. However, FDCs from these older p50-/- mice
exhibited a reduced capacity to trap IgM-IC and retain complement components.
Conclusion: These results demonstrate that while the p50 component of the NF-κB transcription
complex plays an important role in the early development of MZ B cells, MZ B cells can develop
and accumulate in mice lacking this protein. These results highlight the interface between genetic
deficiencies and age, and suggest that different transcription factors may play distinct roles in the
development and maintenance of cell populations at different ages.
Background
Secreted IgM antibodies play important roles in the initial
phases of humoral immune responses. Unlike other anti-
body isotypes, secreted IgM uniquely functions as an adju-
vant, promoting primary antibody responses to sub-
immunogenic doses of T-dependent antigens [1-7]. The
adjuvanticity of IgM is completely dependent on an intact
complement system [7-9]. While mice deficient in
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ogens, these responses are delayed compared to the
immune response of IgM sufficient mice [10-13] Interest-
ingly, pathogens more readily disseminate into vital
organs in secreted IgM-deficient mice, rather than concen-
trate them into secondary lymphoid organs [14]. This sug-
gests that an important role for IgM is to serve as an arbiter
of antigen localization, which may contribute to its adju-
vant function(s).
To investigate how IgM affects the localization of foreign
antigen, a system was developed to follow the fate of IgM-
containing immune complexes (IgM-IC) following their
intravenous (i.v.) administration [7,15] IgM-IC first local-
ize to the splenic marginal zone (MZ), where they are
phagocytized by MZ macrophages and are also bound to
MZ B cells. Binding of IgM-IC to MZ B cells is strictly com-
plement dependent. The MZ B cells subsequently trans-
port the IgM-IC into the B cell follicles where they are
deposited onto follicular dendritic cells (FDCs) [15]. The
important role of MZ B cells in this process was estab-
lished by monitoring IgM-IC deposition onto FDCs in
mice that lacked MZ B cells, either as a result of a genetic
lesion (CD19-deficient mice) that inhibited MZ B cell sur-
vival, or by their depletion using pertussis toxin. In these
mice, little if any IgM-IC was deposited onto FDCs. In
addition, adoptive transfer of B cells with bound IgM-IC
into mice led to IgM-IC deposition onto FDCs. In these
mice, transferred MZ B cells in close proximity to FDCs
were found to have IgM-IC capped and directed toward
the FDC dendrites, strongly suggesting IgM-IC was being
transferred to FDCs by MZ B cells [15].
To further investigate the role of MZ B cells in IgM-IC
transport, we used mice deficient in p50, a member of the
NF-κB family of transcription factors [16]. These mice
have been reported to lack MZ B cells, suggesting an
unambiguous role for this component of the NF-κB tran-
scription factor complex in the development of this subset
of B cells [17]. However, we found that small numbers of
MZ B cells are present in young p50-/- mice, and these cells
are capable of binding high levels of IgM-IC in vivo and in
vitro. Interestingly, MZ B cells were found to accumulate
with age in p50-/- mice such that by 6 months a normal
sized MZ B cell compartment was present. We also found
that p50-/- mice exhibited an accelerated loss of FDC net-
works, as assessed by intense CD21 staining. These data
indicate that MZ B cells can develop in the complete
absence of p50, and suggest that the transcriptional
requirements for the development and/or survival of MZ
B cells might differ in young and old mice.
Results
Presence of MZ B cells in p50-deficient mice
Two month old p50-/- or control C57BL/6 (B6) mice were
injected with IgM-IC and the spleens removed 16 h later.
Based on the reported lack of MZ B cells in p50-/- mice [17]
and the requirement for MZ B cells in the transport and
deposition of IgM-IC onto FDCs [15], we expected that
IgM-IC would not be found localized on FDCs in the
splenic follicles of these mice. However, immunohisto-
chemistry (IH) revealed the presence of IgM-IC on FDCs
in p50-/- mice (Figure 1). The amount of IgM-IC localized
in the spleen follicles of p50-/- mice was substantially less
than in control B6 mice, but none-the-less readily detect-
able. These results could indicate either that IgM-IC can
traffic to FDCs by a previously unanticipated mechanism
independent of MZ B cells, or p50-/- mice may possess
small numbers of MZ B cells that are still functional for
transporting IgM-IC into follicles.
To help discriminate between these alternatives, splenic B
cells from p50-/- mice were analyzed for the presence of
MZ B cells by FACS. MZ B cells can be phenotypically dis-
tinguished from other B cell subsets in the spleen based
on CD21/23 [18,19] and B220/CD1d [20,21]. profiles. As
shown in Figure 2, MZ B cells were, as expected [17],
severely reduced in p50-/- mice. However, small numbers
of B cells fell within the CD21hi/CD23lo and B220+/
CD1dhi gates, at ~10% of the frequency found in the B cell
compartment of control B6 mice. To determine if these
MZ B cells could bind high levels of IgM-IC, spleen cells
from mice that had been injected 1 h earlier were isolated
and the presence of IgM-IC on B cell subsets was deter-
mined by FACS. When IgM-IC were injected into B6 mice,
the complexes were found associated with MZ B cells at
high levels (Figure 2A), as expected from their high level
expression of the complement receptor CR2 (CD21) and
localization at the marginal sinus, which facilitates expo-
sure to blood-borne IgM-IC [15]. In contrast, little if any
of the IgM-IC were present on follicular (FO) B cells. In
p50-/- mice, there was discernable binding of IgM-IC to
MZ B cells (as defined by a shift in the FACS profile)
while, as seen in B6 mice, IgM-IC did not bind to FO B
cells (Figure 2A). This suggests that the cells in the CD21hi
gate in p50-/- mice were authentic MZ B cells. To confirm
this, the capacity of these cells to bind IgM-IC was deter-
mined using in vitro binding assays (Figure 2B). When
p50-/- B cells were incubated with IgM-IC in vitro, MZ B
cells bound higher levels of IgM-IC than did FO B cells (3
to 5 times as assessed by mean fluorescence intensity),
similar to results using B cells from B6 mice.
Note that the spleens of p50-/- mice contain an increased
number of CD21loCD23lo B cells (Fig. 2A; see also Fig.
3A). While we have not explored the identity of these cells
in detail. they are likely to reflect increased numbers ofPage 2 of 11
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of AA4.1+ B cells [22] in the spleens of these mice are
increased (up to 2-fold) over those in age-matched con-
trol B6 mice. As expected from their low levels of CD21,
however, this population of cells does not bind IgM-IC
(data not shown).
MZ B cells can be distinguished as IgMhi B cells positioned
outside of the marginal sinus. To determine whether the
MZ B cells in p50-/- mice were positioned correctly around
the marginal sinus of the spleen, immunofluorescence
(IF) was performed on spleen sections using anti-IgM and
anti-MOMA-1, which stains marginal metallophilic mac-
rophages and delineates the MZ [23]. In control B6 mice,
IgMhi cells (in red) were present in the MZ, outside of the
MOMA-1+ cells (Figure 2C). IgMhi MZ B cells were also
found outside of the MOMA-1 ring in p50-/- mice, but in
reduced numbers, as expected from the drastic reductions
in MZ B cells in these mice (Figure 2A). Taken together,
these data indicate that p50-/- mice contain small numbers
of MZ B cells that are correctly positioned around the mar-
ginal sinus, where they can encounter blood-borne IgM-
IC and transport them into splenic follicles for deposition
onto FDCs.
Accumulation of MZ B cells with age in p50-deficient mice
When older p50-/- mice were analyzed for the presence of
MZ B cells, increased frequencies of MZ B cells were
detected. At 4 months of age, some p50-/- mice contained
increased numbers of MZ B cells, whereas others did not,
p50-/- mice trap IgM-IC less efficiently on FDCsFigure 1
p50-/- mice trap IgM-IC less efficiently on FDCs. Localization of IgM-IC in B6 or p50-/- mice was determined by IH 16 h 
after injection. ER-TR9 identifies marginal zone macrophages (MZM) and FDC-M2 identifies FDCs. IgM-IC (which appear blue 
in this and all subsequent figures and are identified by arrows) are localized to FDCs in spleens from both groups of mice, but 
FDCs from B6 mice show more intense staining, indicating that more IgM-IC are trapped in these mice. All IH stains were per-
formed on serial sections and were developed side-by-side for identical periods of time.Page 3 of 11
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p50-/- mice contain reduced numbers of MZ B cells that bind high levels of IgM-IC A. B cell subsets and IgM-IC bind-
ing. Splenocytes from B6 or p50-/- mice were analyzed for B cell subsets by FACS using CD21/CD23 or B220/CD1d expres-
sion. Histograms on the right show binding of IgM-IC to MZ and FO B cells 1 h after i.v. injection (shaded region); clear profiles 
represent uninjected control mice. Although spleen cells from p50-/- mice contained reduced numbers of MZ B cells, the cells 
present in the MZ B cell gate bind IgM-IC at high levels over background, similar to levels of binding of IgM-IC to B6 MZ B cells. 
B. In vitro binding assay showing binding of IgM-IC to MZ B cells (shaded region) compared with FO B cells (clear region). MZ 
B cells from both B6 and p50-/- mice bind high levels of IgM-IC compared to FO B cells. C. Immunofluorescence shows the 
presence of IgMhi cells (red) in the MZ as demarcated by MOMA-1 (marginal metallophilic macrophages, blue) staining. p50-/- 
mice possess some IgM+ cells in the MZ outside of the MOMA-1 ring, consistent with the presence of appropriately positioned 
MZ B cells in these mice.Page 4 of 11
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time period (data not shown). By 6 months of age, a
phenotypically distinct MZ B cell population was detected
in all of the more than 10 mice analyzed, as determined
by the CD21/23 profile. In these mice, MZ B cells were
present at frequencies comparable to those found in B6
mice (Figure 3A, left panels), although the total number
of splenic B cells did not appear to change. At all ages
tested, p50-/- and B6 mice had similar frequencies of T and
B cells in their spleens, and their spleen sizes were also
similar (unpublished results), and the cellularity of the
spleens (as determined by IH; see for example Fig. 5B)
were also similar, indicating that the increased number of
MZ B cells was selective for this subset of cells. To confirm
p50-/- mice accumulate MZ B cells with age that have the capacity to bind high levels of IgM-ICFigure 3
p50-/- mice accumulate MZ B cells with age that have the capacity to bind high levels of IgM-IC A. FACS profile of 
splenocytes from 2 and 6 month old B6 and 6 month p50-/- mice reveal the presence of normal numbers of MZ B cells in 
spleens of the p50-/- mice. Histograms illustrate binding of IgM-IC to p50-/- MZ B cells as described in Figure 2A. B. In vitro IgM-
IC binding assay. Binding to MZ B cells (shaded profiles); binding to FO B cells (clear profiles).Page 5 of 11
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Phenotypic and histological analysis of MZ B cells in p50-/- mice A. FACS profile of splenocytes from 2 and 6 month 
old B6 and 6 month old p50-/- mice revealed by B220/CD1d and B220/CD9 profiles. B. FACS histograms showing IgM levels on 
MZ and FO B cells (shaded and clear regions, respectively) as determined by CD21/23 profiles. Cells present in the MZ B cell 
gate in p50-/- mice express higher levels of IgM compared with FO B cells, similar to B6 mice. C. IF reveals well demarcated 
IgMhi cells (in red) in the MZ outside of the laminin staining (which identifies the marginal sinus; in green) in 6 month p50-/- mice.Page 6 of 11
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MZ B cells, the expression of other markers of MZ B cells,
including CD1d [20] and CD9 [24], was assessed. As
shown in Figure 4A, populations of B220+ B cells with
CD1dhi and CD9hi phenotypes were present in p50-/- mice,
consistent with the presence of MZ B cells. The frequencies
of these cells were similar to those in aged-matched con-
trol B6 mice. We also assessed the levels of IgM on the
CD21hiCD23lo cells, since MZ B cells express higher levels
of IgM compared with FO B cells [25]. MZ B cells from
p50-/- mice clearly expressed higher levels of IgM than on
FO B cells from these same mice, and at levels similar to
those in control mice (Figure 4B). These B cells were also
positioned within the MZ in p50-/- mice (Figure 4C), as
indicated by the presence of IgM+ cells outside of the mar-
ginal sinus as revealed by laminin staining [26].
As further evidence that the accumulating cells were func-
tional MZ B cells, cells were tested for their capacity to
bind IgM-IC in vivo and in vitro. MZ B cells from 2 and 6
month old B6 mice or from 6 month old p50-/- mice had
high levels of IgM-IC bound following i.v. injection,
whereas FO B cells bound little or no IgM-IC (Figure 3A).
An in vitro binding assay also demonstrated the capacity of
the MZ B cells from p50-/- mice to bind high levels of IgM-
IC compared to FO B cells (Figure 3B). Taken together, the
data demonstrate that while few MZ B cells are present in
young p50-/- mice, they do develop and accumulate with
age, such that by 6 months they have reached normal lev-
els and can functionally bind IgM-IC at high levels, as
would be expected from their increased expression of
CR1/2 (CD21/35).
Deteriorated FDCs in aged p50-/- mice correlates with reduced IgM-IC localizationFigu e 5
Deteriorated FDCs in aged p50-/- mice correlates with reduced IgM-IC localization A. 2 month and 6 month old B6 
mice and 6 month old p50-/- mice were injected with IgM-IC and analyzed by IH for IgM-IC localization 16 h later. IgM-IC were 
present on FDCs in 2 and 6 month B6 mice (see arrows), but were not deposited onto FDCs in p50-/- mice. B. Intense CD21 
staining (designated by arrows) was less visible in the spleens of p50-/- mice, indicating that FDC networks were poorly devel-
oped in these mice. This suggests that reduced IgM-IC localization may be attributed to the loss of functional FDC networks in 
p50-/- mice. The magnifications noted refer to the objective used, not the absolute magnification.Page 7 of 11
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In an effort to determine whether the repopulation of
older p50-/- mice with MZ B cells enabled efficient IgM-IC
trapping, mice were injected with IgM-IC and analyzed for
FDC deposition. Despite the normal levels and position-
ing of MZ B cells, no IgM-IC deposition was observed in
the spleens of 6 month old p50-/- mice (Figure 5A). The
failure of the IgM-IC to localize in the follicles of these
mice could be due to the absence of FDCs. However, as
shown in Figure 5B, FDCs were present in these mice, as
assessed by CD21 staining. However, they appeared to be
much smaller and the dendrites less pronounced than in
age-matched B6 mice, as evident from the diminished
area of intense CD21 staining (Figure 5B, right panels; see
arrows). In addition, the number of follicles with intense
CD21 staining was reduced in the 6 month old p50-/- mice
compared with age matched B6 mice (Figure 5B, 4× view
in left panels). This suggests that the ability of FDCs from
p50-/- mice to retain complement fragments might be
diminished at 6 months of age. Interestingly, 6 month old
B6 mice also exhibited some reduced capacity to trap IgM-
IC (Figure 5A) and slightly reduced CD21 staining com-
pared with younger mice (Figure 5B), suggesting a loss of
FDC function may also be occurring naturally with age, as
previously observed [27]. Consistent with this, FDCs in 6
month old p50-/- and B6 mice could not be detected by
FDC-M2 staining (data not shown), in contrast with
younger mice (Figure 1). FDC-M2 is a FDC specific anti-
body [28] that detects the complement component C4 on
FDCs [29]. The data indicate the loss of FDC function may
be accelerated in mice lacking p50. Together, the data
imply that the lack of FDC localization of IgM-IC in 6
month old p50-deficient mice is not due to functional
inactivity of the MZ B cells that have accumulated in these
mice, but reflects a loss of FDCs and/or FDC function by
this age.
Discussion
Our data demonstrate that while NF-κB p50-/- mice are
clearly deficient in MZ B cells for the first 2 months of life,
MZ B cells appear with age, such that by 6 months a nor-
mal splenic MZ B cell compartment has been reconsti-
tuted. There are at least four distinct but not mutually
exclusive mechanisms that could account for the late
appearance of cells within the MZ of p50-/- mice. First,
these B cells could be memory B cells, which have been
reported to accumulate in the MZ [30]. While we cannot
formally rule out this possibility, B cells from p50-/- mice
respond poorly to antigenic challenge, especially T-
dependent antigens [16]. Consequently, it is unlikely that
memory B cells would be generated in these mice, irre-
spective of their age. Alternatively, the emergence of MZ B
cells in p50-/- mice could represent the accumulation of
these cells through homeostatic proliferation, in which
cells proliferate to fill niches in response to deficits in spe-
cific subsets of cells [31]. While splenic B cells from p50-/
- mice will undergo homeostatic proliferation as a
consequence of their transfer into SCID recipients [32],
the ability of the few MZ B cells in the p50-/- donor spleen
to expand following transfer was not examined [32]. Nev-
ertheless, we view it as unlikely that homeostatic prolifer-
ation accounts for the accumulation of MZ B cells in the
spleens of older p50-/- mice, since the accumulation of
cells brought on by homeostatic proliferation is generally
observed over a much shorter period of time, days to a
couple of weeks, rather than the months required to
reconstitute MZ B cells in p50-/- mice. A third possibility is
that a NF-κB p50-dependent signal transduction pathway
that activates a developmentally required transcription
program in MZ B cells or their precursors is overcome by
compensatory mechanisms with aging. NF-κB p50 is
involved in a number of pathways crucial for B cell devel-
opment and maturation, including B cell receptor (BCR)
signalling and responses to members of the TNF family
[33-35] Signal strength through the BCR has been pro-
posed to be an important determinant of B cell lineage
fate decisions, including the MZ B cell pool [36,37] BAFF
signalling is also important for the selection of B cells into
the MZ B cell pool [38], while an intact LT-β R signalling
pathway is required for the proper positioning of these
cells [39]. The accumulation of MZ B cells in older p50-/-
mice could reflect compensatory mechanisms in one or
more of these signal transduction pathways important for
the emergence or maintenance of MZ B cells. A fourth pos-
sibility is that the small numbers of MZ B cells that
successfully emerge in p50-/- mice survive for extended
periods of time, resulting in the slow accumulation of this
subset of cells with age. Hao and Rajewsky [40] have dem-
onstrated that the half-life of MZ B cells is greater than that
of FO B cells. Thus, a simple explanation for the accumu-
lation of MZ B cells in p50-/- mice with age is that these
cells preferentially survive, and thus their frequency rela-
tive to the FO B cell pool and other B cells in the spleen
increases slowly with age.
B cells from p50-/- mice are compromised in their ability
to respond to specific antigen challenge, and are com-
pletely unresponsive to mitogenic substances such as LPS
[16]. However, our data suggests that MZ B cells from p50-
/- mice display some functionality, including the binding,
transport and deposition of IgM-IC onto FDCs, a function
unique to MZ B cells [15]. Like IgM-containing T-depend-
ent immune complexes, MZ B cells also bind T-independ-
ent type 2 (TI-2) antigens in a complement and CR1/2-
dependent manner [41]. Despite the fact that p50-/- mice
are widely considered to be devoid of MZ B cells, the pres-
ence of small numbers of these B cells in p50-/- mice were
in fact noted in the initial studies of Pillai and colleagues,
and these appeared to bind low levels of TI-2 antigens
[17]. However, further analysis of the consequences ofPage 8 of 11
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FDCs, was not evaluated. The results of the current study
not only extend these previous studies, but demonstrate
that one consequence of the small amount of IgM-IC
binding manifests itself by the limited, but none-the-less
detectable, deposition of these complexes onto FDCs.
This suggests that this function of MZ B cells is completely
independent of the activation of NF-κB, at least those
complexes containing p50. These results extend other evi-
dence suggesting that the activation of MZ B cells through
engagement of the BCR may not be required for transport
and deposition of IgM-IC, since MZ B cells from CD19-
deficient mice, which also have deficits in MZ B cells, are
also functional in this assay [15].
Together, these results raise the question of whether MZ B
cells require activating signals to migrate into B cell folli-
cles following IgM-IC binding to CR1/2. MZ B cell migra-
tion can be detected in 1 h or less after the binding of IgM-
IC [15]. The binding of IgM-IC to these cells may interfere
with one or more of the mechanisms proposed to play a
role in MZ B cell positioning, including retention by mac-
rophages within the MZ [42], integrin-mediated retention
[39], or responsiveness to lysophospholipids in the blood
[43]. Once released, the MZ B cells would be expected to
migrate into follicles in response to chemoattractants such
as BLC [44]. These considerations suggest that follicular
migration of MZ B cells may be the "default" pathway,
whereas BCR engagement, which is known to direct MZ B
cells not into the follicles but to the T-B interface [45-47],
actively alters the fate of antigen specific MZ cells away
from follicular migration.
Despite the increase in frequency (and numbers) of MZ B
cells in p50-/- mice, the deposition of IgM-IC within the
follicles does not improve with age, but declines severely.
This appears to be due to a decrease in function of FDCs,
which are fewer in number and are less pronounced, as
evidenced by CD21 staining (Figure 5). Thus, the
decreased ability of FDCs to retain complement contain-
ing immune complexes observed in old mice [27], appear
to emerge with accelerated kinetics in p50-/- mice.
NF-κB p50 is only one of a growing number of genes,
including a number of transcription factors, whose expres-
sion influences the development of MZ B cells (reviewed
in [48]), highlighting the complex interactions that must
converge to generate this B cell compartment. The fact that
the requirements for individual proteins, such as p50,
could change with age suggests that compensatory mech-
anisms exist which can overcome cellular defects, and/or
that more than one pathway to generate these cells may
exist.
Conclusion
These experiments demonstrate the profound influence
age can exert on cellular populations in genetically modi-
fied mice. The appearance of large numbers of MZ B cells
in 6 month old p50-/- mice suggests that compensatory
mechanisms overcome the deficits caused by p50-defi-
ciency. Both in young and old p50-/- mice, these MZ B cells
appear to retain some functionality, as assessed by their
ability to bind, transport and deposit IgM-IC onto FDCs.
On the other hand, FDCs are unable to maintain their
functional capacity to trap IgM-IC in aged p50-/- mice indi-
cating that, while MZ B cells recover with age, other
immune defects become more pronounced as a result of
deficiency in this member of the NF-κB family of tran-
scription factors.
Methods
Mice
C57BL/6J and NF-κB p50 deficient (B6;129P2-
Nfkb1tm1Bal) [16] mice were purchased from Jackson Lab-
oratories (Bar Harbor, ME). Mice were maintained in the
Laboratory Animal Sciences Center, Boston University
Medical Center. All studies were reviewed by an Institu-
tional Animal Care and Use Committee and carried out in
accordance with established guidelines according to
National Institutes of Health. Mice of both sexes were
used at 2 to 6 months of age as described.
Preparation and injection of IgM-containing immune 
complexes (IgM-IC)
Mice were injected i.v. with a mixture of 15 to 20 µg each
of NP12-BSA-biotin (Biosearch Technologies, Novato, CA)
and affinity purified pentameric IgM anti-NP monoclonal
antibody (B1-8) exactly as previously described [7,15].
In vitro binding assay
In vitro assays to assess the binding of IgM-IC to MZ B cells
were performed as previously described [15]. Briefly, IgM-
IC were formed by mixing 1 µg each of NP-BSA-biotin and
B1-8 IgM in RPMI in the presence of 10% fresh mouse
serum as a source of complement and incubated for 30
minutes at 37°C. Splenocytes (107) were resuspended in
the IgM-IC and incubated at 37°C for an additional 30
minutes. Cells were washed and analyzed by flow
cytometry.
Immunohistochemistry (IH)
Staining of spleen sections was performed exactly as pre-
viously described [7,15]. Briefly, spleens were removed
and snap frozen in O.C.T. Compound (Tissue Tek, Tor-
rance, CA) and stored at -80°C. 6 µm sections were cut
(IEC Microtome, Needham, MA) and fixed in acetone at -
20°C for 10 min. Sections were incubated with 0.3%
H2O2/PBS for 5 min and blocked with 3% normal rabbit
or rat serum. All antibodies were diluted in 5% BSA inPage 9 of 11
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(1/200), anti-CD3-biotin (1/200), anti-CD21/35-FITC
(1/100), (all from BD Biosciences, San Diego), ER-TR9 (1/
200; BMA Biomedical, Augst, Switzerland), and anti-FDC-
M2 (1/200; Immunokontact, Frankfurt, Germany). Sec-
ondary antibodies included anti-FITC-HRP (1/100; Roche
Molecular Biochemicals, Indianapolis, IN), goat anti-rat
IgG-HRP (1/500; Jackson Immunoresearch, West Grove,
PA), and goat anti-rat IgM (Fab')2-HRP (1/1000; Jackson
Immunoresearch). NP12-BSA-biotin and anti-CD3-biotin
was visualized by alkaline phosphatase (AP)-streptavidin
(1/400; Molecular Probes, Eugene, OR) and developed
with napthol AS-MX phosphate/Fast blue BB base (Sigma,
St. Louis, MO). Visualization of antibody stains was
accomplished using horse radish peroxidase (HRP) conju-
gated secondary antibodies developed with 3-amino-9-
ethylcarbazole (Sigma) and H202. After staining, sections
were covered with crystal mount (Biomedia, Foster City,
CA) before examining by digital microscopy (Zeiss, Axio-
vert 200 M, Oberkochen, Germany). Unless otherwise
noted, all images were obtained using a 10× objective (ini-
tial magnification of 100×) unless otherwise noted (see
Fig. 4).
Immunofluorescence (IF)
Sections were initially treated as for IH. Antibodies uti-
lized included anti-MOMA-1 (1/25; Serotec, Raleigh NC)
visualized with a goat anti-rat IgG-AMCA (1/100; Jackson
Immunoresearch), anti-IgM-Texas Red (1/100; BD Bio-
sciences), and anti-laminin (1/500; Sigma) visualized
with an anti-rabbit IgG-FITC (1/100; Jackson Immunore-
search). All sections were covered with Fluoromount G
(Jackson Immunoresearch) and a cover slip before exam-
ining by digital microscopy (Zeiss, Axiovert 200 M,
Oberkochen, Germany).
Flow cytometry
Splenocytes were isolated at the indicated times and
stained as follows. The lymphocyte gate was utilized for
all analysis. Cells were analyzed using a FACScan (Becton
Dickinson, Franklin Lakes, NJ) and FlowJo software (Tree
Star, Ashland, OR). Antibodies utilized were anti-B220-
FITC (1/200), anti-B220-biotin (1/200), anti-B220-PE (1/
200), anti-CD21/35-FITC (1/200), anti-CD23-PE (1/
200), and anti-CD1d-FITC or PE (1/100) (BD Bio-
sciences). Streptavidin-Cy5 (1/200; BD Biosciences) was
used to identify the NP antigen (NP12-BSA-biotin) associ-
ated with lymphocytes, as well as to visualize biotin-
labelled antibodies.
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